Search research articles
Contact Us
Filters
Showing results (41-50 of 65) with videos related to
Page
of 7
Sort By:
Pneumonologia I Alergologia Polska
|
July 29, 2010
[Cell phenotype determines PAI-1 antiproliferative effect - suppressed proliferation of the lung cancer but not prostate cancer cells]
Joanna Chorostowska-Wynimko, Marta Kedzior, Radosław Struniawski, et al.
International Journal of Molecular Sciences
|
January 19, 2018
Can EGCG Alleviate Symptoms of Down Syndrome by Altering Proteolytic Activity?
Marzena Wyganowska-Świątkowska, Maja Matthews-Kozanecka, Teresa Matthews-Brzozowska, et al.
BJU International
|
November 17, 2009
Very long half-life plasminogen activator inhibitor type 1 reduces bleeding in a mouse model
Jerzy Jankun, Steven H Selman, Rick W Keck, et al.
Molecular Cancer Therapeutics
|
January 21, 2003
A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis
Joanna Chorostowska-Wynimko, Rafal Swiercz, Ewa Skrzypczak-Jankun, et al.
International Journal of Molecular Medicine
|
September 28, 2011
Remarkable extension of PAI-1 half-life surprisingly brings no changes to its structure
Jerzy Jankun, Jie Yang, Hong Zheng, et al.
International Journal of Oncology
|
December 9, 2004
In vivo and in vitro effect of baicalein on human prostate cancer cells
Ranko Miocinovic, N Patrick McCabe, Rick W Keck, et al.
Pharmacological Reports : PR
|
October 10, 2009
Accelerated thrombus lysis in the blood of plasminogen activator inhibitor deficient mice is inhibited by PAI-1 with a very long half-life
Jerzy Jankun, Ansari M Aleem, Radosław Struniawski, et al.
International Journal of Molecular Medicine
|
November 4, 2009
Human platelet 12-lipoxygenase: naturally occurring Q261/R261 variants and N544L mutant show altered activity but unaffected substrate binding and membrane association behavior
Ansari M Aleem, Leigh Wells, Jerzy Jankun, et al.
Oncology Reports
|
July 25, 2012
Human 5-, 12- and 15-lipoxygenase-1 coexist in kidney but show opposite trends and their balance changes in cancer
Amira Gohara, Noha Eltaki, Dina Sabry, et al.
Oncology Reports
|
May 8, 2012
L-carnitine and cancer cachexia. II. Effects of lipid emulsion used in total parenteral nutrition on parameters of hemostasis and inflammatory state in L-carnitine deficiency in myocytes
Jarosław Szefel, Wiesław Janusz Kruszewski, Maciej Ciesielski, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 65) with videos related to
Sort By:
Page
of 7
Pneumonologia I Alergologia Polska
|
July 29, 2010
[Cell phenotype determines PAI-1 antiproliferative effect - suppressed proliferation of the lung cancer but not prostate cancer cells]
Joanna Chorostowska-Wynimko, Marta Kedzior, Radosław Struniawski, et al.
International Journal of Molecular Sciences
|
January 19, 2018
Can EGCG Alleviate Symptoms of Down Syndrome by Altering Proteolytic Activity?
Marzena Wyganowska-Świątkowska, Maja Matthews-Kozanecka, Teresa Matthews-Brzozowska, et al.
BJU International
|
November 17, 2009
Very long half-life plasminogen activator inhibitor type 1 reduces bleeding in a mouse model
Jerzy Jankun, Steven H Selman, Rick W Keck, et al.
Molecular Cancer Therapeutics
|
January 21, 2003
A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis
Joanna Chorostowska-Wynimko, Rafal Swiercz, Ewa Skrzypczak-Jankun, et al.
International Journal of Molecular Medicine
|
September 28, 2011
Remarkable extension of PAI-1 half-life surprisingly brings no changes to its structure
Jerzy Jankun, Jie Yang, Hong Zheng, et al.
International Journal of Oncology
|
December 9, 2004
In vivo and in vitro effect of baicalein on human prostate cancer cells
Ranko Miocinovic, N Patrick McCabe, Rick W Keck, et al.
Pharmacological Reports : PR
|
October 10, 2009
Accelerated thrombus lysis in the blood of plasminogen activator inhibitor deficient mice is inhibited by PAI-1 with a very long half-life
Jerzy Jankun, Ansari M Aleem, Radosław Struniawski, et al.
International Journal of Molecular Medicine
|
November 4, 2009
Human platelet 12-lipoxygenase: naturally occurring Q261/R261 variants and N544L mutant show altered activity but unaffected substrate binding and membrane association behavior
Ansari M Aleem, Leigh Wells, Jerzy Jankun, et al.
Oncology Reports
|
July 25, 2012
Human 5-, 12- and 15-lipoxygenase-1 coexist in kidney but show opposite trends and their balance changes in cancer
Amira Gohara, Noha Eltaki, Dina Sabry, et al.
Oncology Reports
|
May 8, 2012
L-carnitine and cancer cachexia. II. Effects of lipid emulsion used in total parenteral nutrition on parameters of hemostasis and inflammatory state in L-carnitine deficiency in myocytes
Jarosław Szefel, Wiesław Janusz Kruszewski, Maciej Ciesielski, et al.
Page
of 7